An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 28 Mar 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Sep 2013 Status changed from not yet recruiting to recruiting, according to a Neurovance media release. Patient recruitment is underway and top-line results are expected in early 2014.
- 17 Sep 2013 Status changed from planning to not yet recruiting, according to ClinicalTrials.gov record.